1-855-378-42281-855-378-4228
One of the outpatient rehabilitation options for individuals in Wamac who are battling with opioid dependence and addiction is called opioid maintenance therapy. Licensed clinics and doctors are authorized to administer specific medications to opioid dependent people, many of which are opioid-based themselves and are habit forming. With low doses however, the individual does not experience high feelings and also does not experience acute cravings and isn't experiencing opioid withdrawal. Methadone is the first medication tried for this sole purpose, but there are alternative options currently to select from.
Methadone is an opiate and is meant to be taken at an outpatient medical center certified to administer the med, which is taken daily as a pill or liquid. The cost of the med is around under $200 per month. Buprenorphine is also an opioid-based drug, and is a pill often taken every other day. But different from Methadone that is only be given in highly well-regulated clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is around $300 a month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, that is a med that reverses the effects of opioids. A person taking this formulation, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and is priced about $450 a month. Naltrexone is an additional drug taken in opioid maintenance therapy, but unlike the other medications mentioned here it's an opioid blocker and is not an opioid. A person has the choice to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, it prevents someone from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 a month.
For All Alcohol and Drug Rehab Facilities In Wamac, Click Here.
